Mass Torts

September 15, 2026

Dupixent Lawsuit for T-Cell Lymphoma

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas.

On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, COPD, and a host of other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different and not one they could have expected.

September 14, 2026

Hernia Mesh Lawsuit

by Ronald V. Miller, Jr.

Currently, thousands of hernia mesh lawsuits are pending in courts across the country. Our hernia mesh lawyers are handling these cases in all 50 states. This page:

Discusses this litigation
Provides the latest 2026 updates and the latest hernia mesh Bard MDL-2846 news on the settlement

September 14, 2026

Olympus Scope Lawsuit

by Ronald V. Miller, Jr.

Between 2013 and 2024, contaminated Olympus duodenoscopes infected hundreds of patients at hospitals across the United States. At least 35 people died.

What happened? These awful infections were caused by dangerous, drug-resistant bacteria that were extremely difficult to treat.

So you had patients who went to the hospital, often getting diagnostic or therapeutic procedures that they did not think would be a big deal, only to come out with infections that damaged organs, required months of intensive care, or, tragically, proved fatal.

September 14, 2026

Ozempic Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are investigating Ozempic lawsuits for patients with NAION, gastroparesis, or gastrointestinal conditions, including bowel obstruction or cyclic vomiting syndrome.

Ozempic is the popular brand name for semaglutide, a prescription drug approved for the treatment of type 2 diabetes. As we all know, Ozempic is also commonly used as a weight management drug. Recent scientific studies have shown that taking Ozempic, particularly at higher doses, can cause gastroparesis.

September 14, 2026

NEC Baby Formula Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are handling Similac and Enfamil infant formula lawsuits for families whose premature babies suffered or died from necrotizing enterocolitis (NEC) after taking one of these formulas. Our law firm is reviewing NEC lawsuits in all 50 states.

Medical research links cow milk-based infant formulas such as Similac and Enfamil to a dangerous neonatal medical condition known as necrotizing enterocolitis. These newborn NEC formula lawsuits make many allegations. At their core, they allege that the makers of these formulas knew of the risk of NEC and did nothing to warn families or give them a choice.

If your premature baby was diagnosed with NEC after being given Similac or Enfamil formula, you may be able to participate in a class action lawsuit against the formula companies and receive financial compensation for the harm that was done to your child.

September 14, 2026

Hair Relaxer Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are reviewing hair relaxer cancer lawsuits on behalf of women throughout the United States. These claims involve women who used chemical hair relaxers or hair straighteners for years and were later diagnosed with uterine cancer, including endometrial cancer, ovarian cancer, or serious uterine fibroids that led to a hysterectomy.

The federal hair relaxer litigation now includes nearly 12,000 plaintiffs. The cases are moving through expert discovery and bellwether preparation in the Northern District of Illinois. No hair relaxer settlement has been announced, and no plaintiff has received a settlement payout through the federal MDL. The latest hair relaxer lawsuit update is that Judge Mary Rowland has lifted a discovery stay for a group of defendants after concluding that settlement discussions had not produced enough progress to justify keeping those cases frozen.

The strongest cases generally involve frequent, long-term use followed by uterine or ovarian cancer, a clear product history, and substantial treatment or reproductive injury.

September 14, 2026

Talc Powder Ovarian Cancer Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are handling baby powder lawsuits in all 50 states in 2026. The talcum powder lawsuits against Johnson & Johnson have been ongoing for years. The lawsuits allege that prolonged use of talcum powder (or “talc”), the active ingredient in products such as Baby Powder and Shower to Shower, can cause ovarian cancer in some women.

This page provides an update on J&J talc powder litigation and discusses the settlement amounts in ovarian cancer lawsuits for victims.

Latest News on J&J Talc Powder Lawsuit Update 2026

September 12, 2026

Monsanto Roundup Lawsuit Update

by Ronald V. Miller, Jr.

In this post, our Roundup lawyers will give you:

An update on where things stand in the new $7.5 billion Roundup class action lawsuit settlement in June 2026
The likely direction the Roundup litigation will take moving forward, and

September 9, 2026

Depo Provera Lawsuit Settlements

by Ronald V. Miller, Jr.

This page is for women considering filing a Depo-Provera lawsuit. Our lawyers provide the latest updates, explain the litigation and settlement process, and offer our assessment of potential Depo-Provera settlement amounts.

Scientific research has found a strong association between prolonged use of injectable medroxyprogesterone acetate, the active drug in Depo-Provera, and intracranial meningioma. Women who received Depo-Provera injections and were later diagnosed with a meningioma are filing lawsuits alleging that Pfizer and related companies failed to provide an adequate warning.

September 9, 2026

Bard PowerPort Lawsuit

by Ronald V. Miller, Jr.

The Bard PowerPort (“BardPort”) is a port catheter device implanted just under the skin to allow for easy attachment to a catheter for the intravenous delivery of fluids or medication.

The Bard PowerPort has inherent design and manufacturing flaws that make the device prone to fracturing and migrating out of position. This can cause severe injuries, including internal vascular damage.

Individuals who suffered injuries due to a defective Bard PowerPort device are now bringing product liability lawsuits against the manufacturer of the PowerPort implants. Our firm is currently accepting new cases from anyone who had a Bard PowerPort port catheter device implanted and was injured due to a fracture, migration, or other implant failures.